research Wound healing with topical BRAF inhibitor therapy in a diabetic model suggests tissue regenerative effects
A topical BRAF inhibitor, vemurafenib, can speed up wound healing and promote hair growth, especially in diabetic patients.
Search
for
Sort by
Research
390-420 / 1000+ results 
research Sublingual tofacitinib for alopecia areata: a roll‐over pilot clinical trial and analysis of pharmacokinetics
The trial showed that a new under-the-tongue treatment for severe hair loss was somewhat effective in a small group of people.
research Reply to: “Tofacitinib for the treatment of severe alopecia areata and variants”
More extensive trials are needed to understand tofacitinib's role in treating severe hair loss.
research Transient Efficacy of Tofacitinib in Alopecia Areata Universalis
Tofacitinib temporarily regrew hair in a man with alopecia, but its effects didn't last.
research Real‐world experience and long‐term evaluation of tofacitinib in refractory alopecia areata: A prospective, open‐label, single‐center study in Asian Arab population
Tofacitinib is a promising treatment for severe alopecia areata, with many patients experiencing complete or partial hair regrowth.
research The usefulness and wellbeing of Tofacitinib in the treatment of Alopecia Areata
Tofacitinib is effective and safe for treating alopecia areata.
research ‘Ritlecitinib: unveiling hair regrowth for alopecia areata’
Ritlecitinib is the first FDA-approved pill for treating significant hair loss in alopecia areata patients aged 12 and up.
research Tumor necrosis factor inhibitors and janus kinase inhibitors in the treatment of cicatricial alopecia: A systematic review
Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.
research Isoginkgetin, a natural biflavonoid from Ginkgo biloba, inhibits inflammatory response in endothelial cells via suppressing NF-κB activation
Isoginkgetin reduces inflammation in cells by blocking NF-κB activation.
research Tofacitinib Loaded Squalenyl Nanoparticles for Targeted Follicular Delivery in Inflammatory Skin Diseases
Tofacitinib nanoparticles can safely and effectively treat alopecia areata by targeting hair follicles.
research Ivarmacitinib in atopic dermatitis presenting with prurigo nodularis-like lesions and alopecia areata: a case report
Ivarmacitinib may effectively treat complex atopic dermatitis and related hair loss.
research 1311 Efficacy of topical tofacitinib in promoting hair growth in non-scarring alopecia
Topical tofacitinib is effective in promoting hair growth for non-scarring alopecia.
research Selective Delivery of Tofacitinib Citrate to Hair Follicles Using Lipid-Coated Calcium Carbonate Nanocarrier Controls Chemotherapy-Induced Alopecia Areata
A new treatment using nanoparticles can effectively prevent and reduce hair loss caused by chemotherapy.
research BH02 Overcoming genetic drivers in alopecia areata: hair regrowth in a patient with the AIRE gene mutation treated with ruxolitinib
Ruxolitinib helped a woman with a genetic mutation regrow her hair and improved her health.
research Adverse events associated with vismodegib: insights from a real-world pharmacovigilance study using the FAERS database
Vismodegib can cause muscle spasms, taste changes, hair loss, fatigue, weight loss, and possibly new issues like skin cancer, dehydration, and swallowing problems, needing close monitoring.
research FDA approves Pfizer's JAK inhibitor for adolescents with alopecia areata hair loss
The FDA approved a new Pfizer drug for hair loss in teens.
research Efficacy and predictive markers of response to tofacitinib and baricitinib therapy in alopecia areata: A 52-week comparative cohort study
Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.
research Upadacitinib for Alopecia Areata in Different Backgrounds: A Case Series
Upadacitinib may effectively treat alopecia areata without side effects.
research Komplet remission ved behandling med JAK-hæmmer hos en patient med alopeciatotalis
Tofacitinib helped a man with alopecia totalis regrow all his hair.
research Benefit and risk profile of tofacitinib for the treatment of alopecia areata: a systemic review and meta‐analysis
Tofacitinib is somewhat effective for alopecia areata, but more research is needed on its safety and long-term effects.
![[4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) Inhibits SCF/c-kit Signaling in 501mel Human Melanoma Cells and Abolishes Melanin Production in Mice and Brownish Guinea Pigs](/images/assets/4eb017dc-711d-4926-bcd0-c3b8f48e3a99/small/19974.jpg)
research [4-t-Butylphenyl]-N-(4-imidazol-1-yl phenyl)sulfonamide (ISCK03) inhibits SCF/c-kit signaling in 501mel human melanoma cells and abolishes melanin production in mice and brownish guinea pigs
ISCK03 stops melanin production in human melanoma cells and lightens skin color in mice and guinea pigs.
research Hair and nail adverse events during treatment with targeted therapies for metastatic melanoma
Targeted therapies for advanced skin cancer often cause hair and nail problems, which need managing to avoid changing the treatment dose.
research Upadacitinib in concurrent Crohn's disease, atopic dermatitis and alopecia areata: A case report
Upadacitinib improved Crohn's disease, atopic dermatitis, and alopecia areata in one patient.
research Recovery of resistant alopecia areata treated with tofacitinib: An 8-year-old child's case report
Tofacitinib helped an 8-year-old child recover from a type of hair loss that is hard to treat.
research Growth inhibition of mouse skin tumor by serine protease inhibitor ONO-3403.
ONO-3403 effectively reduces mouse skin tumor growth without side effects.
research Comparative efficacy and safety of JAK inhibitors in the treatment of moderate-to-severe alopecia areata: a systematic review and network meta-analysis
Brepocitinib 30mg is most effective for moderate-to-severe alopecia areata, but ritlecitinib 50mg may offer a better balance of safety and effectiveness.
research Comparison of the Treatment Outcome of Oral Tofacitinib with Other Conventional Therapies in Refractory Alopecia Totalis and Universalis: A Retrospective Study
Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
research Follicular and epidermal alterations in patients treated with ZD1839 (Iressa), an inhibitor of the epidermal growth factor receptor
ZD1839 (Iressa) causes skin and hair side effects, treatable with tretinoin cream and minocycline.
research Effectiveness and Predictive Factors of Response to Tofacitinib Therapy in 125 Patients with Alopecia Areata: A Single-centre Real-world Retrospective Study
Tofacitinib is effective for treating alopecia areata, and starting treatment early may improve results.
research JAK inhibitors in dermatology: The promise of a new drug class
JAK inhibitors show promise for treating skin conditions like eczema, hair loss, and psoriasis.